VIRGINIA BEACH, Va., Feb. 15, 2025 — LifeNet Health announces the market launch of OraGen®, a novel dental bone allograft. This cryopreserved corticocancellous bone allograft contains endogenous lineage-committed bone cells and demineralized bone matrix. This unique composition provides osteogenicity (bone cell production), osteoconductivity (a scaffold for cell growth), and osteoinduction (stimulation of bone repair).
OraGen is indicated for sinus and ridge augmentation, and repairing significant mandibular or maxillary defects. Building upon LifeNet Health’s success with cellular allografts, OraGen advances dental tissue engineering, enabling rapid and sustained bone formation post-implantation. 1
OraGen prioritizes safety and ease of use. Its rigorous aseptic processing and proprietary cryopreservation (completed within 72 hours) maximize cell viability. Thawing takes under five minutes.
OraGen is available in the U.S. through LifeNet Health’s partner, Salvin Dental Specialties. It offers significant potential for dental surgeons and their patients.
Daniel Osborne, LifeNet Health’s Chief Growth Officer, expressed excitement about the collaboration with Salvin Dental Specialties, highlighting its contribution to improved patient outcomes and advancements in regenerative medicine.
Ken Serota, CEO of Young Innovations (parent company of Salvin Dental Specialties), emphasized Salvin’s commitment to providing innovative regenerative solutions and enhancing patient care through its partnership with LifeNet Health.
LifeNet Health and Salvin Dental Specialties are dedicated to providing high-quality products and exceptional customer service in dental surgery.
About LifeNet Health
LifeNet Health is a global leader in regenerative medicine, offering comprehensive transplant solutions, from organ procurement to bio-implants and cellular therapies. LifeNet Health is dedicated to improving human life through advancements in transplantation and research.
- Gianulis E, Wetzell B, Scheunemann D, et al. Characterization of an advanced viable bone allograft with preserved native bone forming cells. Cell and tissue banking. 2022; (E-pub ahead of print). doi: 10.1007/s10561-022-10044-2.
- Marschall, J. S., Davis, S. S., Jones, L., & Kushner, G. M. Journal of Oral and Maxillofacial Surgery. .
- Hall JF, McLean JB, Jones SM, Moore MA, Nicholson MD, Dorsch KA. Multilevel instrumented posterolateral lumbar spine fusion with an allogeneic cellular bone graft. J Orthop Surg Res. 2019;14(1):372.
- Clinical outcome and explant histology after using a cellular bone allograft in two-stage total hip arthroplasty. Shahrdar C, McLean J, Gianulis E, et al. J Orthop Surg Res. 2020;15(1):16.
For more information:
Doug Wilson
757-609-4468, office
757-348-2931, cell
SOURCE LifeNet Health